Brian G. Feagan, MD

Alimentiv, Inc.; Western University
London, ON, Canada

Presentation(s):

• 1 - Benefits of High versus Low Dose Upadacitinib as Maintenance Treatment in Ulcerative Colitis Patients Who Were Responders to 8-week Induction with Upadacitinib: Results From the U-ACHIEVE Phase 3 Maintenance Trial

  Monday, October 24, 2022
  8:00 AM – 8:12 AM ET

• 40 - Induction Combination Therapy With Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-Blind, Proof-of-Concept VEGA Study

  Tuesday, October 25, 2022
  2:45 PM – 2:55 PM ET